Allspring Global Investments
APLS

Allspring Global Investments’s Apellis Pharmaceuticals APLS Stock Holding History

Allspring Global Investments’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,522
Closed -$188K – 1787
2024
Q3 		$188K Sell
6,522
-65,946
-91% -$2.44M ﹤0.01% 1684
2024
Q2 		$2.78M Sell
72,468
-42,985
-37% -$1.95M ﹤0.01% 1072
2024
Q1 		$6.79M Buy
115,453
+56,178
+95% +$3.58M 0.01% 876
2023
Q4 		$3.55M Sell
59,275
-16,243
-22% -$824K 0.01% 1036
2023
Q3 		$2.87M Sell
75,518
-53,137
-41% -$2.33M 0.01% 1100
2023
Q2 		$11.7M Sell
128,655
-2,256
-2% -$195K 0.02% 744
2023
Q1 		$8.63M Buy
130,911
+4,118
+3% +$238K 0.01% 831
2022
Q4 		$6.56M Buy
126,793
+2,122
+2% +$113K 0.01% 911
2022
Q3 		$8.52M Buy
124,671
+119,363
+2,249% +$7.06M 0.02% 820
2022
Q2 		$240K Sell
5,308
-23,761
-82% -$1.08M ﹤0.01% 1765
2022
Q1 		$1.48M Buy
29,069
+2,301
+9% +$102K ﹤0.01% 1669
2021
Q4 		$1.26M Buy
+26,768
New +$1.05M ﹤0.01% 1796

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Allspring Global Investments's APLS Position: Q4 2024 in Review

Allspring Global Investments sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 6,522 shares — an estimated $188K sold.

Allspring Global Investments first reported a position in APLS in Q4 2021 and held it in 12 quarters. The position peaked at $11.7M in Q2 2023. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Allspring Global Investments reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 6,522 Apellis Pharmaceuticals shares in Q4 2024, an estimated $188K.
  • Allspring Global Investments first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 12 quarters.
  • Allspring Global Investments's Apellis Pharmaceuticals position peaked at $11.7M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.